Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.07
NYSE:DHR's Cash-to-Debt is ranked lower than
93% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. NYSE:DHR: 0.07 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:DHR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.21 Max: N/A
Current: 0.07
Equity-to-Asset 0.53
NYSE:DHR's Equity-to-Asset is ranked lower than
62% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NYSE:DHR: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:DHR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.51 Max: 0.67
Current: 0.53
0.16
0.67
Interest Coverage 16.89
NYSE:DHR's Interest Coverage is ranked lower than
63% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. NYSE:DHR: 16.89 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:DHR' s Interest Coverage Range Over the Past 10 Years
Min: 12.58  Med: 16.69 Max: 22.1
Current: 16.89
12.58
22.1
Piotroski F-Score: 5
Altman Z-Score: 2.95
Beneish M-Score: -2.75
WACC vs ROIC
7.19%
7.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 16.50
NYSE:DHR's Operating Margin % is ranked higher than
85% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. NYSE:DHR: 16.50 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:DHR' s Operating Margin % Range Over the Past 10 Years
Min: 13.79  Med: 16.08 Max: 17.33
Current: 16.5
13.79
17.33
Net Margin % 12.30
NYSE:DHR's Net Margin % is ranked higher than
88% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. NYSE:DHR: 12.30 )
Ranked among companies with meaningful Net Margin % only.
NYSE:DHR' s Net Margin % Range Over the Past 10 Years
Min: 10.3  Med: 13.9 Max: 23.26
Current: 12.3
10.3
23.26
ROE % 9.63
NYSE:DHR's ROE % is ranked higher than
70% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. NYSE:DHR: 9.63 )
Ranked among companies with meaningful ROE % only.
NYSE:DHR' s ROE % Range Over the Past 10 Years
Min: 10.74  Med: 13.64 Max: 17.42
Current: 9.63
10.74
17.42
ROA % 4.97
NYSE:DHR's ROA % is ranked higher than
69% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. NYSE:DHR: 4.97 )
Ranked among companies with meaningful ROA % only.
NYSE:DHR' s ROA % Range Over the Past 10 Years
Min: 5.46  Med: 7.75 Max: 9.03
Current: 4.97
5.46
9.03
ROC (Joel Greenblatt) % 68.91
NYSE:DHR's ROC (Joel Greenblatt) % is ranked higher than
90% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. NYSE:DHR: 68.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:DHR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 59.73  Med: 82.44 Max: 118.82
Current: 68.91
59.73
118.82
3-Year Revenue Growth Rate -2.10
NYSE:DHR's 3-Year Revenue Growth Rate is ranked lower than
69% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NYSE:DHR: -2.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:DHR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 9.7 Max: 47.6
Current: -2.1
-9.7
47.6
3-Year EBITDA Growth Rate -3.30
NYSE:DHR's 3-Year EBITDA Growth Rate is ranked lower than
61% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. NYSE:DHR: -3.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:DHR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -19  Med: 11.7 Max: 51.5
Current: -3.3
-19
51.5
3-Year EPS without NRI Growth Rate -5.50
NYSE:DHR's 3-Year EPS without NRI Growth Rate is ranked lower than
56% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. NYSE:DHR: -5.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:DHR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -33.7  Med: 14.7 Max: 92
Current: -5.5
-33.7
92
GuruFocus has detected 6 Warning Signs with Danaher Corp $NYSE:DHR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:DHR's 10-Y Financials

Financials (Next Earnings Date: 2017-05-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

DHR Guru Trades in Q1 2016

Mario Gabelli 21,900 sh (New)
Ray Dalio 78,785 sh (New)
Caxton Associates 15,000 sh (New)
John Burbank 172,961 sh (+130.61%)
Louis Moore Bacon 73,407 sh (+88.79%)
Daniel Loeb 3,700,000 sh (+64.44%)
First Eagle Investment 3,994,671 sh (+29.23%)
Jim Simons 1,036,600 sh (+20.96%)
Ken Fisher 5,505 sh (+4.28%)
John Hussman 30,000 sh (unchged)
Chuck Akre 1,500,000 sh (unchged)
Julian Robertson Sold Out
John Griffin 2,308,700 sh (-0.27%)
Dodge & Cox 7,366,508 sh (-0.72%)
Manning & Napier Advisors, Inc 1,203,632 sh (-2.48%)
Ruane Cunniff 1,378,586 sh (-3.27%)
Pioneer Investments 2,479 sh (-10.05%)
Murray Stahl 41,233 sh (-13.95%)
Mairs and Power 2,496 sh (-29.37%)
Jeremy Grantham 929,733 sh (-41.07%)
Paul Tudor Jones 15,909 sh (-71.35%)
Steven Cohen 105,000 sh (-74.40%)
» More
Q2 2016

DHR Guru Trades in Q2 2016

Pioneer Investments 34,498 sh (+1291.61%)
Steven Cohen 149,367 sh (+42.25%)
Ruane Cunniff 1,545,881 sh (+12.14%)
Daniel Loeb 3,850,000 sh (+4.05%)
Ken Fisher 5,697 sh (+3.49%)
John Griffin 2,318,700 sh (+0.43%)
John Hussman 30,000 sh (unchged)
Chuck Akre 1,500,000 sh (unchged)
Mairs and Power 2,496 sh (unchged)
Caxton Associates Sold Out
Mario Gabelli 21,751 sh (-0.68%)
Manning & Napier Advisors, Inc 1,093,512 sh (-9.15%)
Dodge & Cox 6,654,158 sh (-9.67%)
Murray Stahl 36,199 sh (-12.21%)
John Burbank 136,257 sh (-21.22%)
Paul Tudor Jones 10,859 sh (-31.74%)
First Eagle Investment 2,324,840 sh (-41.80%)
Jim Simons 534,000 sh (-48.49%)
Ray Dalio 21,885 sh (-72.22%)
Louis Moore Bacon 3,696 sh (-94.97%)
Jeremy Grantham 9,717 sh (-98.95%)
» More
Q3 2016

DHR Guru Trades in Q3 2016

Robert Olstein 47,000 sh (New)
George Soros 7,970 sh (New)
Joel Greenblatt 596,095 sh (New)
Caxton Associates 120,000 sh (New)
Louis Moore Bacon 38,781 sh (+949.27%)
Paul Tudor Jones 65,140 sh (+499.87%)
Ray Dalio 75,600 sh (+245.44%)
Steven Cohen 338,100 sh (+126.36%)
Jim Simons 857,000 sh (+60.49%)
Ruane Cunniff 1,821,908 sh (+17.86%)
Daniel Loeb 4,500,000 sh (+16.88%)
First Eagle Investment 2,450,049 sh (+5.39%)
Ken Fisher 5,760 sh (+1.11%)
John Hussman 30,000 sh (unchged)
Chuck Akre 1,500,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Mairs and Power Sold Out
Pioneer Investments Sold Out
Murray Stahl 36,171 sh (-0.08%)
John Griffin 2,246,000 sh (-3.14%)
Dodge & Cox 5,715,408 sh (-14.11%)
Mario Gabelli 10,751 sh (-50.57%)
Jeremy Grantham 3,826 sh (-60.63%)
John Burbank 40,000 sh (-70.64%)
» More
Q4 2016

DHR Guru Trades in Q4 2016

Paul Tudor Jones 484,432 sh (+643.68%)
Steven Cohen 663,300 sh (+96.18%)
Jim Simons 1,522,100 sh (+77.61%)
First Eagle Investment 3,157,097 sh (+28.86%)
Robert Olstein 55,000 sh (+17.02%)
Chuck Akre 1,655,300 sh (+10.35%)
Mario Gabelli 11,196 sh (+4.14%)
John Hussman 30,000 sh (unchged)
Ray Dalio Sold Out
John Burbank Sold Out
George Soros Sold Out
Caxton Associates Sold Out
Murray Stahl 35,587 sh (-1.61%)
Ruane Cunniff 1,733,275 sh (-4.86%)
Dodge & Cox 5,221,273 sh (-8.65%)
Ken Fisher 5,127 sh (-10.99%)
Jeremy Grantham 3,226 sh (-15.68%)
John Griffin 1,760,000 sh (-21.64%)
Daniel Loeb 3,250,000 sh (-27.78%)
Joel Greenblatt 420,700 sh (-29.42%)
» More
» Details

Insider Trades

Latest Guru Trades with DHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NYSE:TMO, NYSE:Q, NYSE:A, NYSE:LH, NAS:IDXX, NYSE:DGX, OTCPK:SSMXY, OTCPK:ERFSF, NAS:DXCM, NAS:QGEN, NYSE:PKI, NYSE:BIO.B, NAS:ICLR, NYSE:CRL, NAS:PRAH, OTCPK:SWTUY, NAS:CPHD, NAS:BRKR, NAS:VWR, OTCPK:CZMWY » details
Traded in other countries:DHER34.Brazil, DAP.Germany, DHR.Mexico, DHR.Switzerland, 0R2B.UK,
Headquarter Location:USA
Danaher Corp designs, manufactures and markets professional, medical, industrial and commercial products and services. It operates in four segments including Life Sciences; Diagnostics; Dental; and Environmental & Applied Solutions.

Danaher Corp is a diversified and mostly healthcare-focused instrument and supplies manufacturer. The company retains four main business segments: Life Science, Diagnostics, Dental and Environmental & Applied Solutions.

Guru Investment Theses on Danaher Corp

Daniel Loeb Comments on Danaher - Apr 27, 2016

Danaher (DHR) is a diversified multi-industrial company with an increasing exposure to life science and healthcare-oriented businesses. Operating across five different business segments and built up through over 400 acquisitions over the company’s history, the cornerstone for Danaher’s successful integration and value creation strategy has been the

Danaher Business System (DBS). Adapted from Japanese principles of kaizen, DBS has evolved into a set of processes and corporate culture revolving around continuous improvement, helping to drive organic growth and annual margin improvement across Danaher’s portfolio.

In May 2015, Danaher announced the acquisition of a filtration industry leader, Pall Corp, as well as the subsequent split of Danaher into two companies. The split, to be effectuated Q3 2016, will highlight value at both New Danaher – a collection of Danaher’s life science, medical and lower cyclicality businesses – and the spin-off, Fortive – an industrial focused “mini-Danaher”.

New Danaher, representing the large majority of post-split value, will have 60% consumables sales mix, 4% organic growth, 100bps of annual margin expansion, and>100% FCF conversion, an algorithm that will continue the Danaher tradition of compounded earnings growth. The attractive end-market mix, earnings growth, and deep bench of DBS operators will make New Danaher a premium life sciences company that should trade at the high end of its peer group.

Fortive, akin to what Danaher originally looked like two decades ago, will have greatly increased M&A optionality and the ability to deploy free cash flow into assets which have historically received less focus within the Danaher portfolio. With the same DBS roots and team of disciplined operators, Fortive will also provide a multi-year compounding opportunity.

We initiated a position following the announcements last summer which mark a transformational step in Danaher’s decade-long efforts to continuously improve its portfolio of businesses. Despite Danaher’s portfolio of businesses looking more attractive than ever, its current valuation premium to the S&P 500 is modest and remains well below its ten year historical average premium. Over the last ten years, Danaher has compounded at 2x the rate of the S&P 500. We recently added to the position after a meeting with the company reinforced our confidence not only in their operations but also in the company’s culture and importance of their values and principles in driving future success.

From Daniel Loeb (Trades, Portfolio)'s first quarter 2016 shareholder letter.

Check out Daniel Loeb latest stock trades

Sequoia Fund Coments on Danaher - Aug 28, 2015

Terence Paré:



Danaher (NYSE:DHR) is in a lot of different businesses. It started out as an industrial company making things like hand tools and engine retarders. It used to make Craftsman mechanics tools. But the company right now is basically — and in fact has reclassified its documentation with the SEC — to that for industrial instruments. Danaher makes things like oscilloscopes, mass spectrometers. It has a very significant dental business. But it still sells Matco hand tools, which are sold in vans that drive around to garages, industrial printers, medical gear, water treatment equipment, and more.



The business right now is in the headlines a lot because management recently announced that it is going to break Danaher into three pieces and it is going to acquire Pall, which is an industrial filter company. One piece will be Pall and Danaher’s instruments piece, and another will be the industrial businesses. On top of that, Danaher has a communications business. This is part of an earlier acquisition and was originally called Tektronix Communications. Without getting too far under the hood, Tektronix Communications makes gear and software that keep track of the way that the IT infrastructure works in enterprises. For example, it will track if there is some weird glitch going on somewhere in your enterprise system.



Danaher has decided to combine that piece of its business with a company called NetScout, which further complicates things because shareholders are going to be offered the opportunity to swap their Danaher shares for NetScout shares. These are very different businesses from the rest of the company. When the communications piece was in Danaher, it was fun to talk about, but it was relatively small. When it is combined with NetScout, we are going to have to make a decision about how we want to go about dealing with our Danaher stock. I am still working on this. Most of the big news about Danaher has only occurred in the past week or so. So we are still noodling over it. But like Mohawk, Danaher is one of our oldest positions. I think only Berkshire has been in the portfolio longer. Danaher has been a very good investment for us. Where we go from here right now is hard to say because we can elect to own one, two, or three pieces.



One thing I would say, and this speaks to a principle that Bob has pointed to before, and that is that there is significant insider ownership of Danaher by the Rales brothers. They will continue to serve on the boards of both companies after they split it apart. And Jim Lico, a Danaher executive vice president, will serve on NetScout’s board. What is not clear to me is whether or in which entity or entities the Rales brothers are going to elect to receive a percentage of shares disproportionately higher or lower than their current ownership of Danaher. The Rales have made an awful lot of money for themselves — and they have made, relatively speaking on a percentage basis, a lot of money for us. They are not going to do anything ill-advised.



From Ruane, Cunniff & Goldfarb Investor Day 2015 Transcript Part II - Sequoia Fund.



Check out Ruane Cunniff latest stock trades

Top Ranked Articles about Danaher Corp

Humble Attempt to Trumpet a Misjudgment A reflection on what went wrong and what I could have done better with an investment
Joel Greenblatt’s Top 3 New Holdings for the 3rd Quarter The guru invested in commercial products, paper packaging and health care products
Gotham Asset Management’s Joel Greenblatt (Trades, Portfolio) purchased 219 new positions in the third quarter. His top three new holdings are Danaher Corp. (NYSE:DHR), WestRock Co. (NYSE:WRK) and Kimberly-Clark (NYSE:KMB). Read more...
Daniel Loeb Comments on Danaher Guru stock highlight
Danaher (DHR) is a diversified multi-industrial company with an increasing exposure to life science and healthcare-oriented businesses. Operating across five different business segments and built up through over 400 acquisitions over the company’s history, the cornerstone for Danaher’s successful integration and value creation strategy has been the Read more...

Ratios

vs
industry
vs
history
PE Ratio 24.91
DHR's PE Ratio is ranked higher than
66% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. DHR: 24.91 )
Ranked among companies with meaningful PE Ratio only.
DHR' s PE Ratio Range Over the Past 10 Years
Min: 9.61  Med: 14.69 Max: 26.76
Current: 24.91
9.61
26.76
Forward PE Ratio 20.75
DHR's Forward PE Ratio is ranked higher than
53% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. DHR: 20.75 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 24.98
DHR's PE Ratio without NRI is ranked higher than
65% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. DHR: 24.98 )
Ranked among companies with meaningful PE Ratio without NRI only.
DHR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.58  Med: 15.5 Max: 38.03
Current: 24.98
9.58
38.03
Price-to-Owner-Earnings 22.73
DHR's Price-to-Owner-Earnings is ranked higher than
70% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. DHR: 22.73 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DHR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.59  Med: 11.59 Max: 24.42
Current: 22.73
7.59
24.42
PB Ratio 2.42
DHR's PB Ratio is ranked higher than
67% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. DHR: 2.42 )
Ranked among companies with meaningful PB Ratio only.
DHR' s PB Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.86 Max: 2.82
Current: 2.42
1.19
2.82
PS Ratio 3.06
DHR's PS Ratio is ranked higher than
55% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. DHR: 3.06 )
Ranked among companies with meaningful PS Ratio only.
DHR' s PS Ratio Range Over the Past 10 Years
Min: 1.01  Med: 1.86 Max: 4.35
Current: 3.06
1.01
4.35
Price-to-Free-Cash-Flow 21.34
DHR's Price-to-Free-Cash-Flow is ranked higher than
61% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. DHR: 21.34 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DHR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.6  Med: 12.83 Max: 22.92
Current: 21.34
7.6
22.92
Price-to-Operating-Cash-Flow 17.30
DHR's Price-to-Operating-Cash-Flow is ranked higher than
56% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. DHR: 17.30 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DHR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.82  Med: 11.46 Max: 18.59
Current: 17.3
6.82
18.59
EV-to-EBIT 24.24
DHR's EV-to-EBIT is ranked higher than
58% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. DHR: 24.24 )
Ranked among companies with meaningful EV-to-EBIT only.
DHR' s EV-to-EBIT Range Over the Past 10 Years
Min: 8  Med: 12.5 Max: 35.6
Current: 24.24
8
35.6
EV-to-EBITDA 17.30
DHR's EV-to-EBITDA is ranked higher than
58% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. DHR: 17.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
DHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 10.3 Max: 26.1
Current: 17.3
6.7
26.1
Shiller PE Ratio 24.68
DHR's Shiller PE Ratio is ranked higher than
77% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. DHR: 24.68 )
Ranked among companies with meaningful Shiller PE Ratio only.
DHR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.2  Med: 22.74 Max: 35.29
Current: 24.68
15.2
35.29
Current Ratio 1.05
DHR's Current Ratio is ranked lower than
89% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. DHR: 1.05 )
Ranked among companies with meaningful Current Ratio only.
DHR' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.41 Max: 2.23
Current: 1.05
0.9
2.23
Quick Ratio 0.76
DHR's Quick Ratio is ranked lower than
91% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. DHR: 0.76 )
Ranked among companies with meaningful Quick Ratio only.
DHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 0.98 Max: 1.82
Current: 0.76
0.56
1.82
Days Inventory 83.62
DHR's Days Inventory is ranked higher than
52% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. DHR: 83.62 )
Ranked among companies with meaningful Days Inventory only.
DHR' s Days Inventory Range Over the Past 10 Years
Min: 63.09  Med: 71.38 Max: 108.16
Current: 83.62
63.09
108.16
Days Sales Outstanding 59.21
DHR's Days Sales Outstanding is ranked higher than
56% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. DHR: 59.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
DHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.46  Med: 67.29 Max: 97.75
Current: 59.21
54.46
97.75
Days Payable 60.66
DHR's Days Payable is ranked higher than
55% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. DHR: 60.66 )
Ranked among companies with meaningful Days Payable only.
DHR' s Days Payable Range Over the Past 10 Years
Min: 59.9  Med: 70.23 Max: 110.7
Current: 60.66
59.9
110.7

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.67
DHR's Dividend Yield % is ranked lower than
69% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. DHR: 0.67 )
Ranked among companies with meaningful Dividend Yield % only.
DHR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.14  Med: 0.24 Max: 0.84
Current: 0.67
0.14
0.84
Dividend Payout Ratio 0.19
DHR's Dividend Payout Ratio is ranked higher than
87% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.24 vs. DHR: 0.19 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DHR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.03  Med: 0.03 Max: 0.22
Current: 0.19
0.03
0.22
3-Year Dividend Growth Rate 78.60
DHR's 3-Year Dividend Growth Rate is ranked higher than
97% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.60 vs. DHR: 78.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DHR' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 13.2 Max: 78.6
Current: 78.6
0
78.6
Forward Dividend Yield % 0.69
DHR's Forward Dividend Yield % is ranked lower than
73% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. DHR: 0.69 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 6.20
DHR's 5-Year Yield-on-Cost % is ranked higher than
92% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. DHR: 6.20 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DHR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.31  Med: 2.25 Max: 7.89
Current: 6.2
1.31
7.89
3-Year Average Share Buyback Ratio 0.30
DHR's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. DHR: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DHR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.2  Med: -2.1 Max: 20.6
Current: 0.3
-28.2
20.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.22
DHR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
73% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. DHR: 1.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DHR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.17 Max: 4.66
Current: 1.22
0.52
4.66
Price-to-Median-PS-Value 1.64
DHR's Price-to-Median-PS-Value is ranked lower than
82% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. DHR: 1.64 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DHR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.9 Max: 2.05
Current: 1.64
0.2
2.05
Earnings Yield (Greenblatt) % 4.13
DHR's Earnings Yield (Greenblatt) % is ranked higher than
74% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. DHR: 4.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DHR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8  Med: 8 Max: 12.5
Current: 4.13
2.8
12.5
Forward Rate of Return (Yacktman) % 4.07
DHR's Forward Rate of Return (Yacktman) % is ranked lower than
59% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. DHR: 4.07 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DHR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.7  Med: 20.3 Max: 27.2
Current: 4.07
3.7
27.2

More Statistics

Revenue (TTM) (Mil) $18,707
EPS (TTM) $ 3.28
Beta1.04
Short Percentage of Float0.91%
52-Week Range $71.96 - 88.01
Shares Outstanding (Mil)694.02

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 17,922 18,588 19,290
EPS ($) 3.94 4.29 4.60
EPS without NRI ($) 3.94 4.29 4.60
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.10%
Dividends per Share ($) 0.55 0.63 0.71
» More Articles for NYSE:DHR

Headlines

Articles On GuruFocus.com
Danaher Reports First Quarter 2017 Results Apr 20 2017 
Valeant: It's Not a Game of Chess - The Lessons Apr 16 2017 
A Socially Conscious Guru Apr 07 2017 
Chuck Akre Buys Moody's and Dollar General, Sells MasterCard Mar 29 2017 
5 Companies Hit 52-Week Highs Mar 07 2017 
Japan Fund's Best Investments of the Year Dec 27 2016 
Humble Attempt to Trumpet a Misjudgment Dec 14 2016 
A Growth Stock in the Land of Value Stocks? Nov 30 2016 
Joel Greenblatt’s Top 3 New Holdings for the 3rd Quarter Nov 16 2016 
Numerous Companies Reach 52-Week Highs Aug 23 2016 

More From Other Websites
Edited Transcript of DHR earnings conference call or presentation 20-Apr-17 12:00pm GMT Apr 22 2017
Danaher Corp. breached its 50 day moving average in a Bearish Manner : DHR-US : April 21, 2017 Apr 21 2017
Danaher (DHR) Beats Earnings and Revenue Estimates in Q1 Apr 20 2017
Danaher (DHR) Beats Q1 Earnings by a Penny, Guidance Intact Apr 20 2017
Market Recon: If You Are Scared, Don't Show It Apr 20 2017
Danaher beats Street 1Q forecasts Apr 20 2017
Danaher Reports First Quarter 2017 Results Apr 20 2017
Should You Buy Danaher (DHR) Ahead of Earnings? Apr 18 2017
Danaher (DHR) Up 4.5% Since Earnings Report: Can It Continue? Apr 18 2017
Danaher (DHR) Likely to Beat on Q1 Earnings: Stock to Gain? Apr 17 2017
Danaher Corp. : DHR-US: Dividend Analysis : March 31st, 2017 (record date) : By the numbers : April... Apr 11 2017
Will Danaher Continue to Witness Growth on DBS Strength? Apr 10 2017
Blog Coverage Tennant Completes Acquisition of IP Cleaning S.p.A; Announces $300 Million of Senior... Apr 10 2017
A Socially Conscious Guru Apr 07 2017
ETFs with exposure to Danaher Corp. : April 5, 2017 Apr 05 2017
Crane's (CR) Growth Prospects Bright: Should You Buy? Apr 05 2017
Danaher Stock Trades Ex-Dividend Wednesday Mar 28 2017
Here’s where these D.C.-area billionaires rank on Forbes 2017 list Mar 21 2017
Danaher Schedules First Quarter 2017 Earnings Conference Call Mar 20 2017
How to trade deregulation: 6 stocks Mar 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)